The stock of Helius Medical Technologies Inc. (NASDAQ:HSDT) increased by $0.01 on Wednesday to $0.19, up 5.31 percent. The last five days have seen an average of 907,351 shares of common stock traded. 7 times new highs were reached in the current year, with a fall of -$0.1209. The average number of shares traded over the last 20 days was 355,428, while the average volume over the last 50 days totaled 638,813.
HSDT stock appreciated 0.70% since last month. On 08/16/23, the company’s shares reached a one-month low of $0.1680. The stock touched a high of $0.74 on 01/27/23, after rallying from a low of $0.14 in 52 weeks. The price of HSDT stock has declined by -39.30% or -$0.1209 this year, reaching a new high 7 times. Still, the stock price is down -74.71% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
HSDT stock investors should be aware that Helius Medical Technologies Inc. (HSDT) stock had its last reported insider trading activity 243 days ago on Dec 16. On Dec 16, President and CEO ANDREEFF DANE acquired 80,041 shares at $0.25 each. This transaction resulted in the insider spending $19,946. On Nov 23, ANDREEFF DANE added 89,300 shares at a price of US$0.31. After the transaction, the insider now owns 308,003 shares. President and CEO ANDREEFF DANE had earlier bought 10,000 shares on Nov 22 for $0.28 a share. The transaction was completed for $2,834.
Valuation Metrics
Beta for the stock is 1.27. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 6.65, the price-to-book (PB) ratio of 0.85.
Financial Health
For the three months ended June 29, Helius Medical Technologies Inc.’s quick ratio was 7.00, while its current ratio was 7.40, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 41.20% percent. Based on annual data, it had gross profit of $0.32 million and revenue of $0.79 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. HSDT’s return on assets (ROA) during the last 12 months has been -99.70%. There was a -160.50% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -177.70%.
Earnings Surprise
According to Helius Medical Technologies Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $0.26 million, while revenues fell by 0.0% to $0.11 million. It was predicted that Helius Medical Technologies Inc.’s quarterly earnings would be -$0.06, but it ended up being -$0.12. EBITDA was -$3.17 million for the quarter. At the end of Helius Medical Technologies Inc.’s most recent quarter ended June 29, its liabilities totaled 6.18 million, while its total debt was $84000.0. Equity owned by shareholders amounts to $28.3 million.
Technical Picture
Here’s a quick look at Helius Medical Technologies Inc.’s (HSDT) price momentum from a technical perspective. As of 15 August, the RSI 9-day stood at 46.29%, suggesting the stock is Neutral, with a 64.13% historical volatility rate.
The stochastic %K and %D were 21.50% and 22.33% respectively, while the average true range (ATR) was 0.0235. Based on the 14-day stochastic reading of 29.03%, the RSI (14) reading is 47.61%. On the 9-day MACD Oscillator, the stock is at -0.0029.
Analyst Ratings
In its analyst report released on March 24, 2021, Noble Capital Markets began covering Helius Medical Technologies Inc. (NASDAQ: HSDT). The stock was rated as an Outperform by the brokerage firm. Analysts have assigned Helius Medical Technologies Inc. (HSDT) an Buy rating. HSDT is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 3 others recommend it as a buy.
What is HSDT’s price target for the next 12 months?
The current consensus forecast for the stock is between $1.00 and $5.00, with a median target price of $1.70. In analyzing these forecasts, the average price target given by analysts for Helius Medical Technologies Inc. (HSDT) is $2.57.
